State Center for Cell and Gene Therapy, Department of Oncology and Hematology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Leukemia. 2010 May;24(5):914-23. doi: 10.1038/leu.2010.37. Epub 2010 Apr 8.
The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) has an important role in granulopoiesis. The tumor suppressor function of C/EBPalpha is shown by the findings that loss of expression or function of C/EBPalpha in leukemic blasts contributes to a block in myeloid cell differentiation and to leukemia. C/EBPalpha mutations are found in around 9% of acute myeloid leukemia (AML) patients. The mechanism by which the mutant form of C/EBPalpha (C/EBPalpha-p30) exerts a differentiation block is not well understood. By using a proteomic screen, we have recently reported PIN1 as a target of C/EBPalpha-p30 in AML. In the present study, we show that C/EBPalpha-p30 induces PIN1 expression. We observed elevated PIN1 expression in leukemic patient samples. Induction of C/EBPalpha-p30 results in recruitment of E2F1 in the PIN1 promoter. We show that the inhibition of PIN1 leads to myeloid differentiation in primary AML blasts with C/EBPalpha mutations. Overexpression of PIN1 in myeloid cells leads to block of granulocyte differentiation. We also show that PIN1 increases the stability of the c-Jun protein by inhibiting c-Jun ubiquitination, and c-Jun blocks granulocyte differentiation mediated by C/EBPalpha. Our data suggest that the inhibition of PIN1 could be a potential strategy of treating AML patients with C/EBPalpha mutation.
转录因子 CCAAT 增强子结合蛋白α(C/EBPα)在粒细胞生成中具有重要作用。C/EBPα 的肿瘤抑制功能表现在白血病细胞中 C/EBPα 的表达缺失或功能丧失导致髓样细胞分化阻滞和白血病。在大约 9%的急性髓系白血病(AML)患者中发现了 C/EBPα 突变。突变形式的 C/EBPα(C/EBPα-p30)如何发挥分化阻滞作用的机制尚不清楚。通过蛋白质组学筛选,我们最近报道了 PIN1 是 AML 中 C/EBPα-p30 的靶点。在本研究中,我们表明 C/EBPα-p30 诱导 PIN1 的表达。我们观察到白血病患者样本中 PIN1 表达升高。C/EBPα-p30 的诱导导致 E2F1 在 PIN1 启动子上募集。我们表明,PIN1 的抑制导致具有 C/EBPα 突变的原发性 AML 母细胞发生髓样分化。在髓样细胞中过表达 PIN1 会阻止粒细胞分化。我们还表明,PIN1 通过抑制 c-Jun 泛素化来增加 c-Jun 蛋白的稳定性,而 c-Jun 则阻断 C/EBPα 介导的粒细胞分化。我们的数据表明,抑制 PIN1 可能是治疗具有 C/EBPα 突变的 AML 患者的一种潜在策略。